George, Julie http://orcid.org/0000-0002-4272-3683
Maas, Lukas http://orcid.org/0000-0002-5830-6710
Abedpour, Nima http://orcid.org/0000-0002-2933-8035
Cartolano, Maria
Kaiser, Laura http://orcid.org/0000-0002-3212-576X
Fischer, Rieke N.
Scheel, Andreas H. http://orcid.org/0000-0003-0244-1646
Weber, Jan-Philipp
Hellmich, Martin http://orcid.org/0000-0001-5174-928X
Bosco, Graziella
Volz, Caroline
Mueller, Christian
Dahmen, Ilona
John, Felix
Alves, Cleidson Padua
Werr, Lisa http://orcid.org/0000-0002-3697-4136
Panse, Jens Peter
Kirschner, Martin
Engel-Riedel, Walburga
Jürgens, Jessica
Stoelben, Erich
Brockmann, Michael
Grau, Stefan http://orcid.org/0000-0002-9742-527X
Sebastian, Martin
Stratmann, Jan A.
Kern, Jens
Hummel, Horst-Dieter
Hegedüs, Balazs http://orcid.org/0000-0002-4341-4153
Schuler, Martin http://orcid.org/0000-0002-2166-3394
Plönes, Till
Aigner, Clemens http://orcid.org/0000-0002-7787-991X
Elter, Thomas
Toepelt, Karin
Ko, Yon-Dschun
Kurz, Sylke
Grohé, Christian
Serke, Monika
Höpker, Katja
Hagmeyer, Lars
Doerr, Fabian
Hekmath, Khosro
Strapatsas, Judith
Kambartel, Karl-Otto
Chakupurakal, Geothy
Busch, Annette
Bauernfeind, Franz-Georg
Griesinger, Frank
Luers, Anne
Dirks, Wiebke
Wiewrodt, Rainer
Luecke, Andrea
Rodermann, Ernst
Diel, Andreas
Hagen, Volker
Severin, Kai
Ullrich, Roland T.
Reinhardt, Hans Christian
Quaas, Alexander
Bogus, Magdalena
Courts, Cornelius http://orcid.org/0000-0002-9811-8482
Nürnberg, Peter http://orcid.org/0000-0002-7228-428X
Becker, Kerstin http://orcid.org/0009-0009-7897-7181
Achter, Viktor http://orcid.org/0000-0002-3813-0746
Büttner, Reinhard http://orcid.org/0000-0001-8806-4786
Wolf, Jürgen
Peifer, Martin http://orcid.org/0000-0002-5243-5503
Thomas, Roman K. http://orcid.org/0000-0001-9132-4876
Article History
Received: 25 January 2023
Accepted: 7 February 2024
First Online: 13 March 2024
Competing interests
: R.K.T. is a founder of, and consultant to, PearlRiver Bio, acquired by Centessa, and a shareholder of Centessa; a founder and shareholder of, and consultant to, Epiphanes; a founder, shareholder and CEO of DISCO Pharmaceuticals. M.P. is consultant to DISCO Pharmaceuticals. J.G. is consultant to DISCO Pharmaceuticals and received honoraria from MSD. J.W. participated in advisory boards and received lecture fees from Abion, Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Janssen, Lilly, Loxo, Merck, Mirati, MSD, Novartis, Nuvalent, Pfizer, Pierre-Fabre, Roche, Seattle Genetics, Takeda and Turning Point; and additional research support from BMS, Janssen Pharmaceutica, Novartis and Pfizer. M. Schuler is consultant to Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda, received honoraria from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, Roche and Sanofi and received research funding from AstraZeneca and Bristol Myers Squibb. R.B. received honoraria for lectures and advisory boards for AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Illumina, Janssen, Lilly, Merck Serono, MSD, Novartis, Qiagen, Pfizer, Roche and Targos MP/ Discovery Life Sciences. R.B. serves as a member of the board of directors and is a shareholder of Gnothis, Inc. (SE). A.Q. is consultant to Astellas, BMS, MSD, AstraZeneca, Servier and Oncowissen App/TV. R.N.F. received funding from BMS and MSD. J.K. received honoraria from Roche, Sanofi, Boehringer Ingelheim, MSD, BMS/Celgene, Lilly, Takeda, Novartis, AstraZeneca and Pfizer; is consultant to Roche, Boehringer Ingelheim, MSD, BMS/Celgene, Lilly, Takeda, Novartis, AstraZeneca, Pfizer and Janssen; and received travel and congress support from Roche, Sanofi, Boehringer Ingelheim, MSD, BMS/Celgene, Lilly, Takeda, Novartis, AstraZeneca, Pfizer and Janssen. H.-D.H. has participated in advisory board meetings of Amgen and Boehringer Ingelheim, is a steering committee member for Amgen and coordinating or local PI for Amgen, BMS, Revolution Medicines, Boehringer Ingelheim, Merck, Norvatis, AstraZeneca, Dracen, Daiichi Sankyo and AIO-Studien-gGmbH and reports personal fees from Amgen, BMS and Johnson & Johnson. J.P.P. reports personal fees from Apellis/Sobi, Alexion/AstraZeneca, Amgen, Blueprint Medicines, BMS, Boehringer Ingelheim, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi and SwixxBiopharma outside the submitted work. M.K. is consultant to Boehringer Ingelheim, Bayer, BMS, Chugai and Roche and received honoraria from Novartis and Boehringer Ingelheim. L.H. received honoraria and personal fees from Boehringer Ingelheim, BMS, Pfizer, Roche and AstraZeneca. F.J. received scientific support from Merck and AstraZeneca. V.H. is a shareholder of BMS and Johnson & Johnson and received honoraria from Roche, Amgen, Pfizer, Celgene, BMS, Boehringer, Novartis, AstraZeneca and Lilly. F.G. received funding from ASTRA, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Siemens and GSK; has been appointed speaker for ASTRA, Boehringer, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, Abbvie, Siemens, Tesaro/GSK, Amgen and Daiichi Sankyo; and participates in administrative boards for ASTRA, Boehringer, BMS, Celgene, Lilly, MSD, Novartis, Pfizer, Roche, Takeda, Ariad, Abbvie, Tesaro/GSK, Siemens, Tesaro, Amgen and Daiichi Sankyo. C.G. received honoraria from Roche, Sanofi, Boehringer Ingelheim, MSD, BMS/Celgene, Lilly, Takeda, Novartis, AstraZeneca and Pfizer; is consultant to Roche, Boehringer Ingelheim, MSD, BMS/Celgene, Lilly, Takeda, Novartis, AstraZeneca, Pfizer and Janssen; and has received travel and congress support from Boehringer Ingelheim, MSD, Lilly, Takeda, Novartis, AstraZeneca, Pfizer and Janssen. R.T.U. received honoraria from Roche, Boehringer Ingelheim, GSK, PharmaMar and Bayer. C.A. participated on advisory boards and received honoraria from AstraZeneca, Biotest, Bristol Myers Squibb, MSD and Roche; and is a consultant to Ewimed and received research support from Bristol Myers Squibb and PharmaCep—all outside of the submitted work. M. Sebastian reports grants from AstraZeneca; consulting fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Lilly, Roche, Boehringer lngelheim, Amgen, Takeda, Johnson, Merck Serono and GSK; honoraria for lectures from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Lilly, Roche, Boehringer lngelheim, Amgen, Takeda, Johnson, CureVac, BioNTech, Merck Serono, GSK, Daiichi and Pfizer; travel support from Takeda and Pfizer; and membership of the advisory board of CureVac and BioNTech. J.A.S. reports personal fees from Boehringer Ingelheim, AstraZeneca, Roche, BMS, Amgen, LEO pharma, Novartis and Takeda—all outside of the submitted work. All other authors report no competing interests.